Brand-name pharmaceutical firms are disputing a claim that free trade with Europe will cost Canadian consumers $1 billion a year. An industry group Rx&D in a letter to Blacklock’s contradicted testimony by a rival association before the Commons trade committee: “Unfounded speculations…add little value to a meaningful policy discussion.”
This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)
